Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Continued evolution of this drug class has seen the development of single peptides that activate multiple receptors, with incretin peptide sequences engineered to activate additional G-protein-coupled receptors (GPCRs) 8
Nature reviews Immunology
Ohki T, Isogawa A, Toda N, Tagawa K (2016) Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
Experimental Neurology
Two letters cited failure to submit an Investigational New Drug (IND) application for clinical investigations with an investigational new drug, per 21 CFR 312.2(a)
US$ 25.90
US$ 20.51
US$ 21.44
US$ 29.86
US$ 27.10
